| Date: | 2010-05-11 |
| Biotech partner: | Swedish Orphan Biovitrum (Sweden) Biomodels (USA) |
| Type of agreement: | * R&D |
| Compound: | assay for mucositis risk in cancer treatment |
| Disease area: | mucositis risk in cancer treatment |
| Nature of the agreement: | Swedish Orphan Biovitrum and Biomodels have announced a research agreement, under which Biomodels will explore the possibility of developing a clinically applicable screening platform that will define mucositis risk among patients undergoing conditioning regimens for hematopoietic stem cell transplants (HSCT). |
| Financial terms of the agreement: | Swedish Orphan Biovitrum will provide funding for the project. |
